Santhera Pharmaceuticals AG
Im Neuenheimer Feld 518 - 519
80 articles with Santhera Pharmaceuticals AG
Santhera and ReveraGen to Present Findings from Pivotal VISION-DMD Study with Vamorolone at Parent Project Muscular Dystrophy 2021 Conference
Pratteln, Switzerland, and Rockville, MD, USA,June 24, 2021 – Santhera Pharmaceuticals and ReveraGen BioPharma, Inc announce presentations of the positive and statistically highly significant topline results from the VISION-DMD study at the Parent Project Muscular Dystrophy 2021 Virtual Annual Conference.
Santhera Announces Phase 4 LEROS Trial with Raxone® Met Primary Endpoint in Patients with Leber’s Hereditary Optic Neuropathy
Santhera Pharmaceuticals announces positive topline results from itslong-term Phase 4 LEROS study with Raxone® in the treatment of Leber’s hereditary optic neuropathy.The primary endpoint, proportion of eyes with clinically relevant benefit after 12 months treatment with Raxone versus untreated patients from an external control group, was met with high statistical significance.
Santhera and ReveraGen Announce Positive and Statistically Highly Significant Topline Results with Vamorolone in Pivotal VISION-DMD Study
Santhera will hold a conference call / webcast at 16:00 CEST, 15:00 BST, 10:00 EDT. Details are at the end of this statement.
Santhera Pharmaceuticals announces the invitation to its Annual General Meeting, which will be held on June 22, 2021, at 10:30 hrsat the domicile of the Company.
On May 19, 2021, 2,562,375 shares were issued out of the existing authorized capital as treasury shares.
Santhera Pharmaceuticals AG (SIX: SANN) announces that it has issued 2,312,000 treasury shares.
Three biopharma companies recently shuttered their clinical programs after either their compounds failed clinical trials or interim futility analysis suggested they were unlikely to meet their clinical endpoints. Here’s a look.
Santhera said the restructuring will allow the company to focus on the development of vamorolone, a first-in-class dissociative steroid with a novel mode of action that it gained the rights to from ReveraGen BioPharma.
This comes after data from an interim analysis suggested that the trial was unlikely to meet its primary endpoint.
Santhera Announces Publication of Long-term Idebenone Data from SYROS Study in Duchenne Muscular Dystrophy
The objective was to assess the respiratory function evolution during periods of treatment with idebenone
Santhera Pharmaceuticals announces a strategic change to its management team with the appointment of Dario Eklund as CEO, effective December 1, 2019.
Vamorolone Designated Promising Innovative Medicine (PIM) for Treatment of Duchenne Muscular Dystrophy by the UK MHRA
Santhera Pharmaceuticals announces that the UK’s Medicines and Healthcare Products Regulatory Agency has informed ReveraGen BioPharma about having designated vamorolone as Promising Innovative Medicine for the treatment of Duchenne muscular dystrophy
Santhera Announces Presentation by ReveraGen of Positive 18-Month Data with Vamorolone in Duchenne Muscular Dystrophy
Santhera Pharmaceuticals announces presentation of data showing continued improvement of muscle function and improved tolerability compared with corticosteroids of 18-month vamorolone treatment in Duchenne muscular dystrophy.
Santhera to Present Long-Term Data with Puldysa® (Idebenone) in Duchenne Muscular Dystrophy at Upcoming Medical Congresses
Santhera Pharmaceuticals will present data on the therapeutic effects of long-term treatment with Puldysa® in Duchenne muscular dystrophy at the forthcoming medical conferences of the European Paediatric Neurology Society, European Respiratory Society and World Muscle Society.
Pratteln, Switzerland, September 10, 2019 – Santhera Pharmaceuticals announces the online publication of Phase I data with its human neutrophil elastase inhibitor POL6014 in the Journal of Cystic Fibrosis.
Santhera Pharmaceuticals reports first half-year results as of June 30, 2019, and provides an update on its pipeline and strategic focus.
Santhera Announces Publication by ReveraGen of Positive Phase IIa-Extension Study Results with Vamorolone in Patients with Duchenne Muscular Dystrophy
Santhera Pharmaceuticals announces publication by ReveraGen of positive study data with vamorolone in patients with Duchenne muscular dystrophy.
Santhera Pharmaceuticals announces that Christoph Rentsch has decided to step down as Chief Financial Officer of Santhera by end of this year, in order to pursue his career outside the Company.
Pratteln, Switzerland, August 2, 2019 – Santhera Pharmaceuticals announces the closing of the licensing transaction with Chiesi Farmaceutici, an international research-focused healthcare group.
MHRA again confirmed its positive scientific opinion for idebenone under the EAMS while a corresponding European marketing authorization application (MAA) has recently been submitted.